03 apr: Nykredit Realkredit A/S - optagelse til handel og officiel noteri..
03 apr: Meddelelse vedrørende The Drilling Company of 1972 A/S og A.P. Mø..
03-04-2019 09:54:36

Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2019

Company Release no. 06/2019

To: NASDAQ Copenhagen A/S                                                      

Copenhagen, Denmark, 03 April 2019

 

Veloxis Pharmaceuticals A/S - Passing of Annual General Meeting 2019

 

Summary: At Veloxis Pharmaceuticals A/S’ Annual General Meeting held earlier today, all proposals from the Board of Directors were adopted, including approval of the Annual Report.

At the General Meeting, the report by the Board of Directors and Executive Management was acknowledged and the audited Annual Report was approved.

It was decided that the previous year’s net loss of USD 5.285 million is carried forward by transfer to accumulated deficit.

All members of the Board of Directors were re-elected. Hence, the Board of Directors comprises:

  • Michael Thomas Heffernan
  • Mette Kirstine Agger
  • Anders Götzsche
  • Robert Samuel Radie
  • Lars Kåre Viksmoen
  • Paul Kevin Wotton

Subsequent to the Annual General Meeting, the Board of Directors constituted itself with Michael Thomas Heffernan as Chairman of the Board of Directors and Mette Kirstine Agger as Deputy Chairman of the Board of Directors.

Anders Götzsche will be Chairman and Mette Kirstine Agger and Robert Samuel Radie will be members of the Audit Committee. Michael Thomas Heffernan will be Chairman and Lars Kåre Viksmoen will be member of the Nomination Committee. Paul Kevin Wotton will be Chairman and Michael Thomas Heffernan and Mette Kirstine Agger will be members of the Remuneration Committee.

PricewaterhouseCoopers Statsautoriseret Revisionspartnerselskab was re-elected as the Company’s auditor.

The proposed fee to the Board of Directors for the financial year 2019 was approved, and consequently the Board of Directors receives the following in 2019:

Remuneration to the Board of Directors

and board sub-committees (USD)

2019

Chairman of the Board of Directors100,000
Members of the Board of Directors50,000
Chairman of the Audit Committee20,000
Members of the Audit Committee10,000
Chairman of the Remuneration Committee15,000
Members of the Remuneration Committee7,500
Chairman of the Nomination Committee10,000
Members of the Nomination Committee5,000

Further, members of the Board of Directors may receive incentive-based remuneration under the Company's general guidelines for incentive-based remuneration to members of the Board of Directors and Executive Management, ref. Article 16 of the Articles of Association. Each board member will be granted warrants equal to the value of USD 150,000 calculated at the share price on the day of grant.

The proposal by the Board of Directors to authorize the Board of Directors to issue warrants was adopted by the General Meeting, and this resolution was incorporated as Article 5F in the Company's Articles of Association. In accordance therewith the Board of Directors is until 03 April 2024 authorized, at one or more times, to issue up to 17,000,000 warrants, each conferring a right to subscribe for 1 share of nominal DKK 0.1 in the Company, and to implement the corresponding increase(s) of the share capital. The warrants can be issued to employees, executive directors and board members in the Company and its subsidiaries without pre-emptive subscription rights for the Company’s shareholders. The exercise price for warrants, which are issued pursuant to the authorization, shall at a minimum correspond to the market price of the Company’s shares on the date of issuance of the warrants.

The proposal by the Board of Directors to update the Company's remuneration policy including general guidelines for incentive-based remuneration to members of the Board of Directors and Executive Management was approved by the General Meeting, and this resolution was incorporated in the Company's Articles of Association.

The proposal by the Board of Directors to authorize the Board of Directors to increase the share capital was adopted by the General Meeting, and this resolution was incorporated as new Article 6 in the Company's Articles of Association. In accordance therewith the Board of Directors is until 03 April 2024 authorized, at one or more times, to increase the share capital by cash payment up to nominally DKK 17,181,953.50 at market price by issuing new shares, each with a nominal value of DKK 0.1, with or without pre-emptive subscription rights for the Company’s shareholders.

The General Meeting granted the Board of Directors an authorization until the next annual general meeting for the Company to acquire the Company's own shares for up to 10 percent of the Company's share capital at any time, provided that the acquisition, in accordance with the Danish Companies Act Section 197, can be financed by the funds that may be distributed as ordinary dividends. The payment may not divide from the stock price at NASDAQ Copenhagen A/S with more than 10 percent at the time of purchase.

 

For more information, please contact:

 Craig A. Collard    Ira Duarte
 President & CEO  CFO
 Phone: + 1 919 591 3090  Phone: +1 919 591 3090
 Email: cac@veloxis.com  Email: idu@veloxis.com

             

About Veloxis Pharmaceuticals

Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients.  A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals, Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA.  Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the Company's unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs.  The Company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.  For further information, please visit www.veloxis.com.

 

 

Attachment

Veloxis_logo - Color - Screen.png

Relateret indhold
20 maj - 
Mandagens aktier: Simcorp til bunds på direktørsnak
20 maj - 
Aktier/middag: Ambu stiger på aftale - DSV-fald forstær..
20 maj - 
Aktier/åbning: Ambu flyvende fra start og pres på Mærsk
Relateret debat
24 jun - 
@speedfire. Ja, vi bliver klogere om noget tid. Jeg kan..
24 jun - 
helt enig :-)
24 jun - 
I en sådan situation må det være rimeligt ledelsen komm..
Del

Opret kommentar

Relateret debat

  • 1 uge
  • 1 måned
  • 1 År
21 jun
VELO
Mangel på to tacrolimus - konvertere pat. til Envarsus   I USA konvertere de patienter til Envarsus ..
20
21 jun
VELO
Ser ud til at man omkring 1 juli starter et nyt forsøg op med Envarsus hvor man tilsyneladende forve..
17
21 jun
VELO
  Det er en for VELO super bagdør, som har åbnet sig, man kan sige meget tid er spildt uheldig inden..
14
18 jun
VELO
Nogen som har set, denne opdaterede præsentation fra Maj 19 http://ir.veloxis.com/static-files/190d..
14
21 jun
VELO
En fantastisk situation for Veloxis. Det må betyde, at man er gået igang med at konvertere ikke kun ..
13
21 jun
VELO
Masser af god info om manglen på tacrolimus på kan findes på denne side: http://www.emoryhealthca..
12
19 jun
VELO
Ledelsen i Veloxis har en meget forsigtig tilgang til deres forretning, og det er i virkeligheden ud..
11
23 jun
VELO
    Der kan være flere årsager, men det kunne være et bevist valg fra lægens side, idet organet desv..
9
19 jun
VELO
  Tak TB! Selv om vi tager udgangspunkt i deres, efter min vurdering, yderst forsigtige forventninge..
9
19 jun
VELO
Hej Havneholmen. Kun Norvartis Iscalimab CF2533 ser jeg som en seriøs udfordring, på sigt. Dog er de..
8

Euroinvestor spørger: Tryg-aktien stormer frem, kan den blive ved?

23-06-2019 20:35:00
Hos Euroinvestor mener vi, at den bedste kilde til viden om markedet er aktørerne i markedet.Derfor spørger vi hver måned i vores Privatinvestorundersøgelse (PIU) vores brugere om deres forventninger til markeder og økonomi.Du inviteres hermed til at deltage i undersøgelsen. Alle besvarelser er anonyme, og der er ingen krav om login, kontaktoplysninger eller lignende.Vi håber du vil deltage og ser..

Danske Bank: Bestyrelsen fyrer bankdirektør Jesper Nielsen

24-06-2019 08:35:10
Danske Banks bestyrelse har mandag opsagt bankdirektør Jesper Nielsen, der har ansvar for de danske bankaktiviteter.Det fremgår af en meddelelse til fondsbørsen.Opsigelsen sker i forbindelse med sagen om Flexinvest Fri, lyder det.- Jesper Nielsen har gjort en betydelig indsats i banken gennem mange år, senest som midlertidig administrerende direktør, hvilket vi takker ham for.- Men i den konkrete ..

Aktier/tendens: Ørsted står til stigning efter stor sejr i USA

24-06-2019 08:09:35
Efter at have trukket sig sejrrigt ud af en budrunde i USA står Ørsted over for en positiv mandag, mens det generelle danske aktiemarked ligger til en mere moderat udvikling.Godt en time før børsåbning herhjemme peger de amerikanske indeksfutures mod mindre stigninger, og det samme gør den britiske FTSE 100-future. Omvendt indikerer den tyske DAX-future et lille fald.Udsigten til en mandag morgen ..

Mest læste nyheder

  • 24 timer
  • 48 timer
  • 1 uge
1
Dybvad: Så alvorlig en sag at vi måtte skride til fyring
2
Danske Bank: Bestyrelsen fyrer bankdirektør Jesper Nielsen
3
Danske Bank: Finanstilsynet kalder sag for "meget alvorlig"
4
Vestas/Sydbank: Spansk konkurrent er foran på point i kampen
5
Aktier/middag: Danske Bank bankes ned efter farvel til CEO-vikar

Relaterede aktiekurser


Copyright Berlingske Media 2019  Handelsbetingelser  |  Cookiedeklaration  |  Cookie- og Privatlivspolitik  |  Ophavsret og vilkår
Aktieinformation leveres af Morningstar.
Data er forsinket 15-20 minutter iht. de enkelte børsers regler om videredistribution.
 
25. juni 2019 03:32:35
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20190527.1 - EUROWEB5 - 2019-06-25 03:32:35 - 2019-06-25 03:32:35 - 1 - Website: OKAY